Healthcare industry

High-tech - 20/10/2016

Industry 4.0 in the medical technology and pharmaceutical industry sectors

The digitalisation of industry affects the entire value chain. From individual products to digitising workflows in companies and connecting companies with clients and service providers via the Internet of Things – Industry 4.0 makes completely new manufacturing processes possible and requires new and specific business models.

Article - 13/09/2016

Catalent – galenics experts from Schorndorf

Pharmaceutical and biotechnology companies are working intensively on the discovery and development of new drugs for the efficient and safe treatment of diseases. However, before drugs are authorised for treating humans and animals, they have to be made into a form that is acceptable. That is where a company called Catalent Pharma Solutions, with a facility in Schorndorf in the south of Germany, comes in.

Company profile - 25/07/2016

300MICRONS: 3D cell culture solutions tailored to customer needs

What happens in tissues and organs and how do they react to pharmaceutical substances? Three-dimensional cell cultures can reproduce reality far better than a single-cell layer can. With good reason. Reality is far from two-dimensional. A company called 300MICRONS GmbH develops films with tiny indentations that provide optimal conditions for cells to grow into 3D cell aggregates.

BioLAGO and BIOPRO to start new diagnostics project - 07/07/2016

DiagNeeds: translating clinical requirements into new products

(Lake Constance/Stuttgart) – BioLAGO e.V. and BIOPRO Baden-Württemberg GmbH are working together on the “DiagNeeds” project to bring hospitals and medical professionals closer to diagnostics providers in order to facilitate the development of new diagnostic procedures. There will be special focus on topics that are currently of major interest in the field of diagnostics, including liquid biopsies, companion diagnostics, point-of-care diagnostics…

Article - 20/06/2016

New diagnostic tool for greater health safety when dealing with multidrug-resistant pathogens

Infections with antibiotic-resistant bacteria and diseases such as breast or colon cancer are among the major causes of death worldwide. Early diagnosis is therefore key for the identification of people affected and for providing immediate therapy. The R&D service provider Hahn-Schickard and its partners are currently working on the development of a rapid and simple diagnostic system that can detect life-threatening infections and cancer at…

Medical technology - 14/03/2016

The operating room of the future: minimally invasive and future-oriented intervention techniques

Being able to diagnose and treat tumour patients in just a few hours is just one of the many promising goals of the Fraunhofer Project Group for Automation in Medicine and Biotechnology (PAMB). The overall goal of the Intervention and Therapy research group is to take innovative technologies for diagnostic and therapeutic interventions from laboratory development to prototype production for use in clinical trials.

Article - 02/02/2016

EU consortium to speed up innovations in the healthcare sector

EIT Health is a large-scale European project launched in December 2014 that aims to help people in Europe to live a healthier life and stay active as they grow older. The consortium brings together 140 leading companies and institutions from 14 European countries and has a total budget of two billion euros. It is one of the largest networks worldwide in the healthcare sector.

Article - 21/01/2016

Genome research as information research

DNA sequencing has become indispensable in modern science. Innovative advances that will bring about changes in the life sciences and medicine are due to rapid developments in genome analysis technologies. In the interview below, Peter Pohl, CEO and co-founder of GATC Biotech AG, explains why DNA sequencing will become even more important in future.

Article - 18/01/2016

New approaches in the life sciences industry: innovative strategies for courageous companies

For many years, the pharmaceutical industry has been investing increasing amounts of money in the development of new products. Dr. Friedemann Taut, a specialist in anaesthesia, intensive care, emergency medicine and clinical pharmacology as well as founder and managing director of Taut Science & Service Ltd. a consultanca for Medical Device and Drug Development, explains in the following interview why small- and mid-sized companies can stay a…

Digitalisation - 10/12/2015

cubuslab helps laboratories to enter the digital era

cubuslab, a start-up company that was spun off from the Karlsruhe Institute of Technology in March 2015, has developed a technology to connect different types of laboratory equipment, from precision balances to analytical instruments. The technology is aimed at automating workflows and connecting and storing data in an electronic laboratory notebook.

Press release - 16/11/2015

The Baden-Württemberg healthcare industry – a strong economic power

(Stuttgart – 16th November 2015) BIOPRO Baden-Württemberg has just published its latest analysis of the Baden-Württemberg healthcare industry including comprehensive facts and figures. Baden-Württemberg continues to be one of the top locations for medical technology, pharma and biotechnology in Germany.

Telemedizin - 19/10/2015

SMARTY – a new way to treat and care for chronically ill children

Chronic and complex diseases in children are often a heavy burden on their families. Parents naturally want their children to have the latest treatment, and children are usually treated by several specialists. This makes it rather difficult, or, at the very least, involves considerable effort to keep everyone up to date. Dr. Joachim Riethmüller from the University Children’s Hospital in Tübingen and his team of doctors are using telemedicine in…

Article - 14/10/2015

High-throughput technologies and bioinformatics from a single source – the Quantitative Biology Center (QBiC)

“Omics” is a current buzz word used to describe comprehensive investigations in many areas of the life sciences. In practice, omics refers to fields of scientific study that involve a huge number of experiments and even more data. Evaluating and managing all the data within a fixed period is a huge challenge for most researchers working on their own. It was to address these issues that the Quantitative Biology Center – QBiC for short – was…

Press release - 30/09/2015

Vetter Embarks on a 300 Million Euro Investment Strategy for Further Development To its Manufacturing Sites and to make available Additional Manufacturing Capacities

Vetter has announced that in keeping with its commitment to providing customers with the manufacture of high quality drug products, the company will invest approximately 300 million euros to expand and upgrade its manufacturing facilities over an estimated five-year period. As a leading contract development and manufacturing organization, Vetter is continuously developing its manufacturing sites and techniques to prepare them for future needs and…

Article - 04/05/2015

“Persistence leads to success” - corporate development in the biotech sector

For graduates with innovative business ideas, becoming independent entrepreneurs can be an interesting alternative to traditional career paths. This is exactly what Dr. Reinhold Horlacher thought 15 years ago. He had just been awarded his PhD from the University of Konstanz, and had a business idea that he decided to turn into reality by establishing a company called Trenzyme GmbH. In the following interview with BIOPRO, he describes his…

BIOPRO Baden-Württemberg GmbH is the central point of contact for the healthcare industry in Baden-Württemberg. If you have questions relating to the “Baden-Württemberg Healthcare Industry” portal, please feel free to contact BIOPRO’s editorial office. Questions about the healthcare industry in general or BIOPRO’s healthcare industry services should be addressed to BIOPRO’s Team Healthcare.

As a 100% affiliate of the Baden-Württemberg government, BIOPRO Baden-Württemberg GmbH provides targeted support to the pharmaceutical industry and the biotechnology and medical technology sectors as well as supporting the development of a bioeconomy.

Baden-Württemberg is home to numerous technology parks and thus offers an excellent infrastructure and attractive high-tech locations for life sciences companies in close proximity to scientific excellence. Young companies and business start-ups particularly stand to benefit from the opportunities for cooperation with other companies and research institutions in the technology parks and also from the relatively cheap rents for office and…

Setting up an independent company is an excellent way to turn innovative life sciences solutions into successful new products and services. Baden-Württemberg is highly attractive for business startups. As one of the leading German states in the fields of healthcare and biotechnology, Baden-Württemberg has an attractive and stimulating environment for those seeking to set up their own company. Baden-Württemberg has a high density of innovative…

Baden-Württemberg is currently home to 173 biotechnology companies. In addition to dedicated biotechnology companies, this also includes bioinformatics, diagnostics and analytics companies that use modern biotechnology methods or focus on biotechnological production.

Article - 23/03/2015

Crowdfunding: a new source of money for the healthcare sector?

Crowdfunding has become a popular widely-talked-about financing tool that opens up new ways of acquiring money for projects that might not otherwise receive backing. The financing model is based on the simple idea of raising many small amounts of capital to finance a large project. In early 2015 a company called Riboxx secured the capital it needed through a campaign on the Seedmatch crowdfunding platform. The German company aescuvest GmbH…

Article - 02/02/2015

Rentschler Biotechnologie invests in new production plant

The Laupheim-based contract manufacturer Rentschler Biotechnologie GmbH is greatly expanding its production capacities. The company is investing €24 million in the construction of two 3,000 litre stainless steel bioreactors, which should be operational in early 2017 and will more than double the production capacities for cell culture-derived proteins. Rentschler also announced recently that it was adding a new 2,000 litre single-use bioreactor…

Press release - 08/01/2015

Biotech-Cluster Rhine-Neckar (BioRN) leads InnoLife consortium to success

BioRN is a member of the consortium InnoLife, which has won the call for the Knowledge and Innovation Community (KIC) Healthy Living and Active Ageing (EIT Health) of the European Institute for Innovation and Technology (EIT). With a grant volume of up to 700 million euros and a total project volume of more than 2 billion euros, this is one of the largest publicly funded initiatives in the health sector worldwide.

Article - 22/12/2014

Bioinformaticians shed light into the data jungle

In recent years, the University of Tübingen has developed a tightly integrated service structure for the computer-based management of life sciences data. This structure is the point of contact for all those that produce or work with “omics” data – in Tübingen and beyond.